Lyophilized lymph nodes improved CAR T cell delivery

Introduction:

Many factors hinder CAR T cell efficacy in solid tumours. Strategies have been developed to enhance CAR T therapy via controlled T cell release, mimicking activation signals, and localized amplification (1). Here, we propose using patient-derived lyophilized lymph nodes (L-LNs) for CAR T cell delivery to prevent tumour recurrence. LNs support lymphocyte homeostasis, supplying essential nutrients for cell recruitment and survival (2). As LNs are often removed for prognostic information (3), they can serve as biocompatible, autologous carriers for therapeutic delivery, including CAR T cells.

Zhen Gu – Professor, Zhejiang University; Hongjun Li – Professor, Zhejiang University